Delving into the Latest Updates on ZHB103 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Target-

Mechanism-

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Ischemic Attack, TransientIschemic strokeAcute Ischemic Stroke

Inactive Indication-

Originator Organization

Zonhon Biopharma Institute, Inc.

Active Organization

Zonhon Biopharma Institute, Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估ZHB103注射液在健康受试者中单次和多次肌肉注射给药的安全性和耐受性。次要目的：评估ZHB103注射液在健康受试者中单次和多次肌肉注射给药后的药代动力学特征和药效学特征。评估ZHB103注射液在健康受试者中单次和多次肌肉注射给药后的免疫原性。

[Translation]

Primary objective: To evaluate the safety and tolerability of single and multiple intramuscular injections of ZHB103 injection in healthy subjects. Secondary objective: To evaluate the pharmacokinetic and pharmacodynamic characteristics of ZHB103 injection after single and multiple intramuscular injections in healthy subjects. To evaluate the immunogenicity of ZHB103 injection after single and multiple intramuscular injections in healthy subjects.

Start Date-

Sponsor / Collaborator

Zonhon Biopharma Institute, Inc.

100 Clinical Results associated with ZHB103

Login to view more data

100 Translational Medicine associated with ZHB103

Login to view more data

100 Patents (Medical) associated with ZHB103

Login to view more data

100 Deals associated with ZHB103

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ischemic Attack, Transient	Phase 1	CN	Zonhon Biopharma Institute, Inc.	14 Oct 2024
Ischemic stroke	Phase 1	CN	Zonhon Biopharma Institute, Inc.	14 Oct 2024
Acute Ischemic Stroke	IND Approval	CN	Zonhon Biopharma Institute, Inc.	25 Dec 2023